ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

Leukemia & Lymphoma

LLS Precision Medicine Trial May Change Treatment Paradigm for AML Patients

The Leukemia & Lymphoma Society will head up the Beat AML Master Trial, which will use a precision medicine protocol under the support and guidance from the FDA. Image © Minerva Studio/Shutterstock.com 

Leukemia & Lymphoma

Researchers at Weill Cornell Medicine are reporting that they have successfully converted cells from blood vessels in mice into blood-forming stem cells.

Researchers at Seattle Children's Research Institute announced the first-in-human clinical trial aimed to extend remission for children and young adults with leukemia treated with CAR T-cell immunotherapy.

A new study is suggesting that intravenous and subcutaneous rituximab share similar efficacy and safety profiles.

On April 28, 2017, the US Food and Drug Administration approved midostaurin (Rydapt) for treating newly diagnosed FLT3-mutated acute myeloid leukemia and three types of systemic mastocytosis.

Kinase oncoproteins and growth factors both activate the proto-oncogene c-FOS and DUSP1, allowing the persistence of residual leukemia cell populations despite tyrosine kinase inhibitor therapy.

Patients with mucosa-associated lymphoid tissue (MALT) lymphoma had improved event-free survival when treated with chlorambucil plus rituximab compared with either therapy alone.

Unmutated immunoglobulin heavy chain variable region gene (IGHV) status does not adversely impact survival among ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Pages

Subscribe to Leukemia & Lymphoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.